IMS Health, the world’s leading provider of market intelligence to the
pharmaceutical and healthcare industries, today announced the completion
of its acquisition by entities created by certain affiliates of TPG
Capital, L.P. (“TPG”) and the CPP Investment Board (“CPPIB”).
“As a private company, we will continue to innovate
for client needs and look forward to working with our new partners as we
capitalize on our expanding opportunity in the healthcare market.”
“This transaction has delivered significant value to our shareholders
and is a strong endorsement of our business model, our teams and the
leadership position we have built,” said IMS Health Chairman and CEO
David R. Carlucci. “As a private company, we will continue to innovate
for client needs and look forward to working with our new partners as we
capitalize on our expanding opportunity in the healthcare market.”
“We are delighted to be working with the talented IMS management team
to drive growth by expanding the company’s market
intelligence offerings, which are crucial to the healthcare industry,”
said James Coulter, founding partner, TPG.
Mark Wiseman, senior vice-president, Private Investments, CPP Investment
Board said, “IMS is a world-class company with a strong management team
and excellent growth prospects. We look forward to working with
management to position IMS for success over the long term.”
Pursuant to the terms of the merger agreement, IMS Health’s stockholders
are entitled to receive $22.00 in cash, without interest, less any
applicable withholding taxes, for each share of IMS Health common stock
owned by them. As a result of the merger, IMS Health’s common stock will
no longer be listed for trading on the New York Stock Exchange.
Stockholders of record will receive a letter of transmittal and
instructions on how to surrender their shares of IMS Health common stock
in exchange for the merger consideration. Stockholders of record should
wait to receive the letter of transmittal before surrendering their
shares.